Synapse - Works

Results (116517)

ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation

Meeting Abstract

Abou-Alfa, G. K.; Macarulla Mercade, T.; Javle, M.; Kelley, R. K.; Lubner, S.; Adeva, J.; Cleary, J. M.; Catenacci, D. V.; Borad, M. J.; Bridgewater, J. A.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

Meeting Abstract

Yau, T.; Park, J. W.; Finn, R. S.; Cheng, A. L.; Mathurin, P.; Edeline, J.; Kudo, M.; Han, K. H.; Harding, J. J.; Merle, P.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Assessment of cardiotoxicity (CT) associated with doxorubicin (dox) in patients (pts) with advanced soft tissue sarcoma (STS) in a phase III randomized trial

Meeting Abstract

Jones, R. L.; Wagner, A.; Kawai, A.; Shahir, A.; Soldatenkova, V.; Wright, J.; Tap, W. D.
Annals of Oncology (2019)

Fulltext@MSK | Save

Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma

Meeting Abstract

Gounder, M. M.; Merriam, P.; Ratan, R.; Patel, S. R.; Chugh, R.; Villalobos, V.; Thorton, M.; Van Tine, B. A.; Abdelhamid, A. H.; Joshi, P.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option

Meeting Abstract

Liu, S. V.; Duruisseaux, M.; Tolba, K.; Branden, E.; Goto, Y.; Weinberg, B. A.; Renouf, D. J.; Doebele, R. C.; Heining, C.; Schlenk, R. F.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)

Meeting Abstract

Tolaney, S. M.; Wardley, A. M.; Zambelli, S.; Hilton, J.; Troso-Sandoval, T.; Ricci, F.; Im, S. A.; Kim, S. B.; Johnston, S. R. D.; Chan, A.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Integrated safety analysis of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with ovarian cancer in the treatment and maintenance settings

Meeting Abstract

Kristeleit, R. S.; Oza, A. M.; Oaknin, A.; Aghajanian, C.; Tinker, A. V.; Tredan, O.; O'Malley, D. M.; Leary, A.; Konecny, G. E.; Lorusso, D.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis

Meeting Abstract

Lee, C. H.; Shah, A. Y.; Makker, V.; Taylor, M. H.; Shaffer, D.; Hsieh, J. J.; Cohn, A. L.; DiSimone, C.; Pinto Marin, A.; Rasco, D. W.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Health-related quality of life in patients with metastatic Merkel cell carcinoma receiving second-line or later avelumab treatment: 36-month follow-up data

Meeting Abstract

D'Angelo, S. P.; Nolte, S.; Schlichting, M.; Henry-Szatkowski, M.; Hennessy, M.; Bharmal, M.
Annals of Oncology (2019)

Fulltext@MSK | Save

Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

Meeting Abstract

De Braud, F. G. M.; Siena, S.; Barlesi, F.; Drilon, A.; Simmons, B. P.; Huang, X.; Ye, C.; Doebele, R. C.
Annals of Oncology (2019)

Fulltext@MSK | Save